Cargando…

Retracted: Allogeneic Natural Killer and Cytomegalovirus (CMV)-pp65 Pulsed Dendritic Cells Induced Complete Response Through 15 Months in a Patient with Recurrent Glioblastoma: A Case Study

Retraction Notice: The manuscript contains inaccurate regulatory details about the treatment used in this case.

Detalles Bibliográficos
Autores principales:	Gumrukcu, Serhat, Nguyen, Tung X., White, Rachel L., Howell, Gregory T., Musikanth, Phillip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2022
Materias:	Retracted
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272575/ https://www.ncbi.nlm.nih.gov/pubmed/35788133 http://dx.doi.org/10.12659/AJCR.937680

Ejemplares similares

Allogeneic Natural Killer and Cytomegalovirus (CMV)-pp65 Pulsed Dendritic Cells Induced Complete Response Through 15 Months in a Patient with Recurrent Glioblastoma: A Case Study
por: Gumrukcu, Serhat, et al.
Publicado: (2021)

EPCT-13. CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS
por: Landi, Daniel, et al.
Publicado: (2020)

Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients
por: Wakefield, Amanda, et al.
Publicado: (2015)

Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation
por: Dieamant, Débora C, et al.
Publicado: (2013)

A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation
por: Gentile, Giuseppe, et al.
Publicado: (2006)

Expression of CMV protein pp65 in cutaneous malignant melanoma
por: Agnarsdóttir, Margrét, et al.
Publicado: (2019)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Intrathecal cytomegalovirus immunoglobulin for CMV encephalitis post allogeneic stem cell transplantation
por: Pang, Ian, et al.
Publicado: (2022)

Deciphering the Immunological Phenomenon of Adaptive Natural Killer (NK) Cells and Cytomegalovirus (CMV)
por: Barnes, Samantha, et al.
Publicado: (2020)

Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia
por: Piñana, José Luis, et al.
Publicado: (2019)

Cytomegalovirus (CMV)-specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation
por: Wang, Xiaodong, et al.
Publicado: (2021)

CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects
por: Slezak, Stefanie L, et al.
Publicado: (2007)

Human cytomegalovirus tegument proteins (pp65, pp71, pp150, pp28)
por: Tomtishen III, John Paul
Publicado: (2012)

A Mortality Analysis of the Cytomegalovirus (CMV) Infection Letermovir Prophylaxis Trial in CMV-Seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation (HCT)
por: Maertens, Johan, et al.
Publicado: (2017)

Cytomegalovirus (CMV) Infection and Latency
por: O’Connor, Christine M.
Publicado: (2021)

Mass cytometry reveals immune signatures associated with cytomegalovirus (CMV) control in recipients of allogeneic haemopoietic stem cell transplant and CMV‐specific T cells
por: McGuire, Helen M, et al.
Publicado: (2020)

Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors
por: He, Ran, et al.
Publicado: (2011)

“Targeted” Screening for Cytomegalovirus (CMV)-Related Hearing Loss: It’s Time for Universal CMV Screening in the NICU!
por: Medoro, Alexandra, et al.
Publicado: (2017)

Targeting cytomegalovirus (CMV) antigens for GBM immunotherapy
por: Nair, Smita K, et al.
Publicado: (2013)

Cytomegalovirus (CMV) seroprevalence in the adult population of Germany
por: Lachmann, Raskit, et al.
Publicado: (2018)

Acute Cytomegalovirus (CMV) Hepatitis in an Immunocompetent Adult
por: Zahid, Maleeha, et al.
Publicado: (2020)

Comparison of Quantitative Cytomegalovirus Real-time PCR in Whole Blood and pp65 Antigenemia Assay: Clinical Utility of CMV Real-time PCR in Hematopoietic Stem Cell Transplant Recipients
por: Choi, Su-Mi, et al.
Publicado: (2009)

Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients
por: Lee, Sae-Mi, et al.
Publicado: (2017)

1104. Risk Factors and Outcomes of Refractory and/or Resistant Cytomegalovirus (CMV) Infection after Allogeneic Hematopoietic Stem Cell Transplantation
por: Karantoni, Eleni, et al.
Publicado: (2020)

926. Risk factors for post-letermovir cytomegalovirus (CMV) reactivation in allogeneic hematopoietic stem cell transplant (HSCT) recipients
por: Mendoza, Maria Alejandra, et al.
Publicado: (2023)

Correlation of Cytomegalovirus (CMV) Disease Severity and Mortality With CMV Viral Burden in CMV-Seropositive Donor and CMV-Seronegative Solid Organ Transplant Recipients
por: McBride, Jacqueline M, et al.
Publicado: (2019)

Determination of human cytomegalovirus pp65 antigenemia among renal transplant patients
por: Moses, S., et al.
Publicado: (2012)

604 Risk Factors for Cytomegalovirus (CMV) Reactivation in CMV-seropositive Liver Transplant Patients
por: Bruminhent, Jackrapong, et al.
Publicado: (2014)

THE PREVALENCE OF CYTOMEGALOVIRUS (CMV) VIRURIA AMONG HOSPITALIZED CHILDREN AND THE RISK OF CMV ACQUISITION BY NURSES
por: Adler, Stuart P, et al.
Publicado: (1984)

Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients
por: Seo, Euri, et al.
Publicado: (2021)

Detection of cytomegalovirus (CMV) by digital PCR in stool samples for the non-invasive diagnosis of CMV gastroenteritis
por: Gu, Jia, et al.
Publicado: (2022)

Correction: Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients
por: Seo, Euri, et al.
Publicado: (2023)

Enhanced Induction of T Cell Immunity Using Dendritic Cells Pulsed with HIV Tat and HCMV-pp65 Fusion Protein In Vitro
por: Park, Jung-Sun, et al.
Publicado: (2011)

Pp65 antigenemia and cytomegalovirus diagnosis in patients with lupus nephritis: report of a series.
por: Lino, Katia, et al.
Publicado: (2018)

Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation
por: Rea, Federico, et al.
Publicado: (2016)

Detection of Cytomegalovirus (CMV) in Saliva of Congenitally Infected Neonates
por: Wissel, Mark, et al.
Publicado: (2017)

Cytomegalovirus (CMV) Pneumonitis: Cell Tropism, Inflammation, and Immunity
por: Fonseca Brito, Luís, et al.
Publicado: (2019)

Antiviral Treatment of Maternal and Congenital Cytomegalovirus (CMV) Infections
por: Pinninti, Swetha, et al.
Publicado: (2023)

Impact of CMV Infection on Natural Killer Cell Clonal Repertoire in CMV-Naïve Rhesus Macaques
por: Truitt, Lauren L., et al.
Publicado: (2019)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lucg66t1hja7l0ts1t2s9dnjcj